| ELVN |
Enliven Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$135M |
|
6.02M |
|
Commodore Capital LP |
30 Jun 2025 |
| RLAY |
Relay Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$88.7M |
$19.1M |
17M |
+27.3% |
Commodore Capital LP |
30 Sep 2025 |
| ASMB |
ASSEMBLY BIOSCIENCES, INC. |
Common Stock, par value $0.001 |
9.9% |
$29.3M |
|
1.62M |
|
Commodore Capital LP |
08 Aug 2025 |
| SABS |
SAB BIOTHERAPEUTICS, INC. |
Common Stock, $0.0001 par value per share |
9.9% |
$9.59M |
|
4.52M |
|
Commodore Capital LP |
26 Sep 2025 |
| PALI |
PALISADE BIO, INC. |
Common Stock, par value $0.01 per share |
9.9% |
$5.62M |
|
9.69M |
|
Commodore Capital LP |
01 Oct 2025 |
| ANRO |
Alto Neuroscience, Inc. |
Common Stock, $0.0001 par value per share |
9.8% |
$12.8M |
|
3.19M |
|
Commodore Capital LP |
20 Oct 2025 |
| COGT |
Cogent Biosciences, Inc. |
Common Stock, $0.001 Par Value |
7.2% |
$147M |
$54.6M |
10.2M |
+59.3% |
Commodore Capital LP |
30 Sep 2025 |
| DRUG |
Bright Minds Biosciences Inc. |
Common Shares, without par value |
7.2% |
$15.4M |
|
500K |
|
COMMODORE CAPITAL LP |
31 Dec 2024 |
| TERN |
Terns Pharmaceuticals, Inc. |
Common Stock, $0.0001 par value per share |
6.5% |
$42.8M |
$7.89M |
5.7M |
+22.6% |
Commodore Capital LP |
30 Sep 2025 |
| TYRA |
Tyra Biosciences, Inc. |
Common Stock, $0.0001 par value per share |
6.3% |
$47.2M |
$8.74M |
3.38M |
+22.7% |
Commodore Capital LP |
30 Sep 2025 |
|
LB PHARMACEUTICALS INC |
Common Stock, $0.0001 par value per share |
5.5% |
|
|
1.23M |
|
Commodore Capital LP |
11 Sep 2025 |
| AMLX |
Amylyx Pharmaceuticals, Inc. |
Common Stock, $0.0001 par value per share |
5.1% |
$89.2M |
|
5.65M |
|
Commodore Capital LP |
10 Nov 2025 |
| NRIX |
Nurix Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
4.9% |
$34.9M |
-$646K |
3.78M |
-1.82% |
Commodore Capital LP |
30 Sep 2025 |
| MRUS |
Merus N.V. |
Common Shares, (euro) 0.09 nominal value per share |
4.7% |
$192M |
-$12.3M |
3.53M |
-6% |
Commodore Capital LP |
30 Jun 2025 |
| CLDX |
Celldex Therapeutics, Inc. |
Common Stock, par value $.001 |
4.6% |
$78.3M |
-$8.32M |
3.03M |
-9.6% |
Commodore Capital LP |
30 Sep 2025 |
| VRDN |
Viridian Therapeutics, Inc.\DE |
Common Stock, $0.01 par value |
3.9% |
$69.1M |
-$23.7M |
3.2M |
-25.6% |
Commodore Capital LP |
30 Sep 2025 |
| NGNE |
Neurogene Inc. |
Common Stock, $0.000001 par value |
3% |
$9.17M |
|
428K |
|
Commodore Capital LP |
30 Jun 2025 |
| CELC |
Celcuity Inc. |
Common Stock, $0.001 par value per share |
2.9% |
$12.1M |
|
1.1M |
|
COMMODORE CAPITAL LP |
31 Dec 2024 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
2% |
$56M |
-$56.5M |
585K |
-50.2% |
Commodore Capital LP |
30 Sep 2025 |
| NKTX |
Nkarta, Inc. |
Common Stock, $0.0001 par value per share |
0.5% |
$742K |
|
352K |
|
COMMODORE CAPITAL LP |
31 Dec 2024 |
| CRDF |
Cardiff Oncology, Inc. |
Common Stock |
0% |
$0 |
-$21.9M |
0 |
-100% |
Commodore Capital LP |
30 Jun 2025 |
| SLDB |
Solid Biosciences Inc. |
Common Stock $0.001 par value per share |
0% |
$0 |
-$31.6M |
0 |
-100% |
Commodore Capital LP |
30 Jun 2025 |